BioMarin Reports Third Quarter 2026 Financial and Operating Results

BioMarin posts record $1.025 billion Q3 revenue but GAAP net loss widens on acquisition costs.

What the company is saying

BioMarin highlights a milestone quarter, with total revenues surpassing $1 billion for the first time, driven by a 32% year-over-year increase. The company credits this growth to the acquisition of Amicus Therapeutics and increased demand for its medicines, particularly in Metabolic Conditions, which saw a 44% revenue jump. CEO Alexander Hardy frames the narrative around portfolio diversification, pipeline expansion, and sustainable future growth, emphasizing the addition of four new assets in 2026 and the integration of Amicus. The announcement details regulatory progress for VOXZOGO, including upcoming FDA and EMA decisions, and underscores the global reach of its therapies, with more than 75% of VOXZOGO revenue generated outside the U.S. The company is transparent about the drivers of its increased GAAP net loss, citing acquisition-related amortization, interest expense, and IPR&D charges, while also pointing to improved non-GAAP profitability. The tone is confident and forward-looking, with specific guidance updates and cost synergy targets presented as evidence of execution.

What the data suggests

The disclosed figures show robust top-line growth, with Q3 2026 revenues at $1.025 billion, up 32% from $776 million in Q3 2025. Metabolic Conditions revenue rose 44% to $744 million, with GALAFOLD and POMBILITI + OPFOLDA contributing $152 million and $49 million, respectively, following their acquisition. VOXZOGO revenue increased 12% to $245 million, with a 17% rise in global patients treated, and more than 75% of this revenue coming from outside the U.S. Non-GAAP income for the quarter more than doubled to $45 million from $22 million, and non-GAAP operating margin improved to 13.4% from 2.8%. However, GAAP net loss widened to $123 million from $31 million, primarily due to acquisition-related costs, including $320 million in Alesta acquisition charges and $83 million from the BMN 450 license, which together negatively impact EPS by $1.87 for the year. The company expects $280 million in GAAP cost synergies from the Amicus integration by 2028. Updated 2026 guidance reflects order timing uncertainty, with total revenues now forecast at $3.8–$3.9 billion and non-GAAP diluted EPS at $2.80–$3.10. The royalty agreement with Ascendis Pharma A/S provides 20% of Yuviwel net U.S. sales and 18% in the EU, Brazil, and South Korea until May 2030. Overall, the data supports the narrative of strong revenue momentum and pipeline expansion, but also highlights the impact of acquisition and integration costs on GAAP profitability.

Analysis

The announcement is generally positive, with strong realised revenue growth (32% YoY) and improved non-GAAP profitability, both supported by detailed numerical disclosures. However, the tone is somewhat inflated relative to the underlying profitability, as GAAP Net Loss increased significantly due to acquisition and integration costs. While the company provides specific guidance for 2026 and details on pipeline progress, a substantial portion of the narrative focuses on forward-looking synergies, cost savings, and regulatory milestones that will not be realised until 2027–2028. The capital intensity is high, with large outlays for acquisitions and integration, but the full benefits (e.g., $280 million in synergies) are only expected in 2028. Some clinical claims (e.g., 'durable motor function') are not substantiated with data. Overall, the gap between narrative and evidence is moderate: realised operational growth is strong, but the path to sustained profitability remains dependent on successful integration and future pipeline outcomes.

Risk flags

• ●Acquisition and integration costs have materially increased GAAP net loss, with $320 million in Alesta charges and $83 million from the BMN 450 license impacting 2026 EPS by $1.87. If integration is delayed or synergies are not realized, profitability could remain under pressure.
• ●Guidance for 2026 revenues and EPS has been revised downward due to order timing uncertainty, indicating exposure to large, lumpy international orders and potential volatility in quarterly results.
• ●The realization of $280 million in cost synergies from the Amicus integration is not expected until 2028, introducing execution risk over a multi-year horizon.
• ●Pipeline expansion is highlighted as a growth driver, but several assets are in early or mid-stage development, and regulatory approvals for VOXZOGO are not expected until 2027, adding clinical and regulatory risk.
• ●Royalty income from Ascendis Pharma A/S is contingent on Yuviwel sales in multiple jurisdictions through May 2030, exposing BioMarin to commercial and geographic execution risk outside its direct control.

Bottom line

BioMarin delivered record quarterly revenues of $1.025 billion, driven by recent acquisitions and strong demand for its metabolic and skeletal condition therapies, but GAAP net loss widened to $123 million due to significant acquisition and integration charges. The company's updated 2026 guidance reflects both continued revenue momentum and the financial drag of recent deals, with non-GAAP EPS now forecast at $2.80–$3.10. While non-GAAP profitability and operating margins have improved, the path to sustained GAAP profitability depends on realizing $280 million in cost synergies by 2028 and successful integration of acquired assets. Key regulatory decisions for VOXZOGO are expected in early and mid-2027, which could unlock further growth if successful. The royalty agreement with Ascendis Pharma adds a new revenue stream but carries execution risk. Investors should focus on the company's ability to deliver on synergy targets, manage integration costs, and achieve regulatory milestones in the next 12 months. The main takeaway is that BioMarin's operational growth is strong, but acquisition-related costs and execution risks remain material.

Announcement summary

(NASDAQ:BMRN) BioMarin Pharmaceutical Inc. reported third quarter 2026 total revenues of $1.025 billion, representing a 32% year-over-year increase, marking the first time quarterly revenue exceeded $1 billion. The revenue growth was driven by a 44% year-over-year increase in Metabolic Conditions revenue to $744 million and a 12% increase in Skeletal Conditions revenue, with significant contributions from GALAFOLD ($152 million) and POMBILITI + OPFOLDA ($49 million), both acquired on April 27, 2026. The number of patients treated with GALAFOLD and POMBILITI + OPFOLDA increased by approximately 13% and 69% year-over-year, respectively. VOXZOGO revenue grew 12% year-over-year to $245 million, with the number of children treated globally increasing 17% year-over-year, and more than 75% of VOXZOGO revenue generated outside the United States. As of quarter-end, children with achondroplasia in 58 countries were being treated with VOXZOGO. BioMarin updated its full-year 2026 guidance, now expecting total revenues between $3,800 million and $3,900 million, Metabolic Conditions revenue between $2,675 million and $2,750 million, and VOXZOGO revenue between $975 million and $1,025 million. Non-GAAP Diluted EPS guidance was revised to $2.80 to $3.10. GAAP Net Loss for the quarter increased to $123 million from $31 million in the prior year, primarily due to the Amicus Therapeutics acquisition and related costs, as well as acquired in-process R&D charges from the Alesta Therapeutics acquisition. Non-GAAP Income for the quarter increased to $45 million from $22 million in the prior year. BioMarin expects approximately $280 million of GAAP cost synergies (approximately $220 million on a Non-GAAP basis) from the Amicus integration to be fully realized in 2028. The company announced a global settlement with Ascendis Pharma A/S regarding Yuviwel, under which Ascendis will pay BioMarin a royalty equal to 20% of net sales in the U.S. and 18% in the European Union, Brazil, and South Korea until May 2030. Four new assets were added to the pipeline in 2026, including BMN 450 for Fabry disease, BMN 440 for hypophosphatasia, BMN 430 for ReNU syndrome, and BMN 820 for focal segmental glomerulosclerosis. The FDA set a PDUFA action date of May 30, 2027, for VOXZOGO for hypochondroplasia, and the EMA validated its submission for VOXZOGO to treat HCH. The application for full approval of VOXZOGO in children with achondroplasia is under FDA review with a PDUFA action date of February 28, 2027. The Phase 2/3 study for BMN 333 continues to enroll, with dose-response data expected in 2027. Five-year results from the PROPEL study with POMBILITI + OPFOLDA showed durable motor function and stabilization of pulmonary function in adults with late-onset Pompe disease. BioMarin will host a conference call and webcast to discuss these results on November 2, 2026, at 4:30 p.m. ET.

Disagree with this article?